Biomedical Engineering Reference
In-Depth Information
generate mono- and bispecific antibodies. Protein Eng. Des.
Sel. 24(5), 447-454.
29. Hinton PR, Xiong JM, Johlfs MG, Tang MT, Keller S,
Tsurushita N. (2006) An engineered human IgG1 antibody
with longer serum half-life. J. Immunol. 176(1), 346-356.
30. Correale P, Cusi MG, Tagliaferri P. (2011) Immunomodulatory
properties of anticancer monoclonal antibodies: is the “magic
bullet” still a reliable paradigm? Immunotherapy 3(1), 1-4.
31. Desjarlais JR, Lazar GA. (2011) Modulation of antibody
effector function. Exp. Cell Res. 317(9), 1278-1285.
32. Vaccaro C, Zhou J, Ober RJ, Ward ES. (2005) Engineering the
Fc region of immunoglobulin G to modulate in vivo antibody
levels. Nat. Biotechnol. 23(10), 1283-1288.
33. Fast JL, Cordes AA, Carpenter JF, Randolph TW. (2009)
Physical instability of a therapeutic Fc fusion protein: domain
contributions to conformational and colloidal stability. Bio-
chemistry 48(49), 11724-11736.
34. Molineux G, Newland A. (2010) Development of romiplos-
tim for the treatment of patients with chronic immune
thrombocytopenia: from bench to bedside. Br.J.Haematol.
150(1), 9-20.
35. Huang C. (2009) Receptor-Fc fusion therapeutics, traps, and
MIMETIBODY technology. Curr. Opin. Biotechnol. 20(6),
692-699.
36. Jazayeri JA, Carroll GJ. (2008) Fc-based cytokines: prospects
for engineering superior therapeutics. BioDrugs 22(1), 11-26.
37. Mayle KM, Le AM, Kamei DT. (2012) The intracellular
trafficking pathway of transferrin. Biochim. Biophys. Acta
1820(3), 264-281.
38. Chen X, Lee H-F, Zaro JL, Shen W-C. (2011) Effects of
receptor binding on plasma half-life of bifunctional transferrin
fusion proteins. MolPharm 8(2), 457-465.
39. Wang Y, Chen Y-S, Zaro JL, Shen W-C. (2011) Receptor-
mediated activation of a proinsulin-transferrin fusion protein in
hepatoma cells. J. Control. Release 155(3), 386-392.
40. Kim B-J, Zhou J, Martin B, Carlson OD, Maudsley S, Greig
NH, et al. (2010) Transferrin fusion technology: a novel
approach to prolonging biological half-life of insulinotropic
peptides. J. Pharmacol. Exp. Ther 334(3), 682-692.
41. Gustavson SM, Chen D, Somayaji V, Hudson K, Baltrukonis
DJ, Singh J, et al. (2011) Effects of a long-acting GLP-1
mimetic (PF-04603629) on pulse rate and diastolic blood
pressure in patients with type 2 diabetes mellitus. Diabetes
Obes. Metab. 13(11), 1056-1058.
42. Park E, Starzyk RM, McGrath JP, Lee T, George J, Schutz AJ,
et al. (1998) Production and characterization of fusion proteins
containing transferrin and nerve growth factor. J. Drug Target.
6(1), 53-64.
43. Debinski W. (2002) Local treatment of brain tumors with
targeted chimera cytotoxic proteins. Cancer Invest. 20(5-6),
801-809.
44. Osborn MJ, McElmurry RT, Peacock B, Tolar J, Blazar BR.
(2008) Targeting of the CNS in MPS-IH using a nonviral
transferrin-alpha-L-iduronidase fusion gene product. Mol.
Ther. 16(8), 1459-1466.
45. Vanhove B, Laflamme G, Coulon F, Mougin M, Vusio P,
Haspot F, et al. (2003) Selective blockade of CD28 and not
CTLA-4 with a single-chain Fv-alpha1-antitrypsin fusion anti-
body. Blood 102(2), 564-570.
46. Dennis MS, Zhang M, Meng YG, Kadkhodayan M, Kirchhofer
D, Combs D, et al. (2002) Albumin binding as a general
strategy for improving the pharmacokinetics of proteins.
J. Biol. Chem. 277(38), 35035-35043.
47. Langenheim JF, Chen WY. (2009) Improving the pharmaco-
kinetics/pharmacodynamics of prolactin, GH, and their
antagonists by fusion to a synthetic albumin-binding peptide.
J. Endocrinol. 203(3), 375-387.
48. Nguyen A, Reyes AE2nd, Zhang M, McDonald P, Wong WLT,
Damico LA, et al. (2006) The pharmacokinetics of an albumin-
binding Fab (AB.Fab) can be modulated as a function of
affinity for albumin. Protein Eng. Des. Sel. 19(7), 291-297.
49. Dennis MS, Jin H, Dugger D, Yang R, McFarland L, Ogasa-
wara A, et al. (2007) Imaging tumors with an albumin-binding
Fab, a novel
tumor-targeting agent. Cancer Res. 67(1),
254-261.
50. Smith BJ, Popplewell A, Athwal D, Chapman AP, Heywood S,
West SM, et al. (2001) Prolonged in vivo residence times of
antibody fragments associated with albumin. Bioconjug.
Chem. 12(5), 750-756.
51. Holt LJ, Basran A, Jones K, Chorlton J, Jespers LS, Brewis
ND, et al. (2008) Anti-serum albumin domain antibodies for
extending the half-lives of short lived drugs. Protein Eng. Des.
Sel. 21(5), 283-288.
52. Walker A, Dunlevy G, Rycroft D, Topley P, Holt LJ, Herbert T,
et al. (2010) Anti-serum albumin domain antibodies in the
development of highly potent, efficacious and long-acting
interferon. Protein Eng. Des. Sel. 23(4), 271-278.
53. Nilvebrant J, Alm T, Hober S, Lofblom J. (2011) Engineering
bispecificity into a single albumin-binding domain. PLoS ONE
6(10), e25791.
54. Jonsson A, Dogan J, Herne N, Abrahmsen L, Nygren P-A.
(2008) Engineering of a femtomolar affinity binding protein
to human serum albumin. Protein Eng. Des. Sel. 21(8),
515-527.
55. Andersen JT, Pehrson R, Tolmachev V, Daba MB, Abrahmsen
L, Ekblad C. (2011) Extending half-life by indirect targeting of
the neonatal Fc receptor (FcRn) using a minimal albumin
binding domain. J. Biol. Chem. 286(7), 5234-5241.
56. Tijink BM, Laeremans T, Budde M, Stigter-van Walsum M,
Dreier T, de Haard HJ, et al. (2008) Improved tumor targeting
of anti-epidermal growth factor receptor Nanobodies through
albumin binding: taking advantage of modular Nanobody
technology. Mol. Cancer Ther. 7(8), 2288-2297.
57. Holliger P, Wing M, Pound JD, Bohlen H, Winter G. (1997)
Retargeting serum immunoglobulin with bispecific diabodies.
Nat. Biotechnol. 15(7), 632-636.
58. Hutt M, Farber-Schwarz A, Unverdorben F, Richter F, Kon-
termann RE. (2012) Plasma half-life extension of small recom-
binant antibodies by fusion to immunoglobulin-binding
domains. J. Biol. Chem. 287(7), 4462-4469.
Search WWH ::
Custom Search